Notably, navitoclax can demonstrate on-target inhibition of BCL-XL in platelets, inducing clinically unacceptable thrombocytopenia (30, 31), but surprisingly, we observed no decrease in platelet counts over the course of the mouse xenograft experiment (Supplementary Fig. S6C). The gene discussed is BCL2L1; the disease is Thrombocytopenia.